Soleno Therapeutics, Inc. (NASDAQ: SLNO) is trending higher in pre-market trading as markets react to Neurocrine’s acquisition deal.
Neurocrine Biosciences has announced an agreement to acquire Soleno Therapeutics for $53.00 per share in cash, valuing the transaction at $2.9 billion. This acquisition will bring VYKAT™ XR, a first-in-class therapy for Prader-Willi syndrome, into Neurocrine’s portfolio, strengthening its position in the fields of endocrinology and rare diseases.
Neurocrine plans to initiate a cash tender offer for all outstanding shares of Soleno’s common stock at $53.00 per share. This offer represents a 34 percent premium over Soleno’s closing price on April 2, 2026, and a 51 percent premium over its 30-day volume-weighted average price.
In pre-market trading, Soleno Therapeutics changed hands at $52.39, versus a prior close of $39.49.
 is trending higher in pre-market trading as markets react to Neurocrine's acquisition deal.){kind=link}